RP-HPLC In-Vitro Dissolution Method Development and Validation for Determination of Olmesartan Medoxomil, Chlorthalidone and Cilnidipine Drug Combinations / Pranavkumar Shah, Bhavin Dhaduk
Objective: A simple, sensitive, and accurate in-vitro dissolution method has been developed for Olmesartan Medoxomil (OLM), Chlorthalidone (CHLR) & Cilnidipine (CIL) drug combination according to USP dissolution testing methodologies with different discriminating mediums and validated as per ICH guidelines. Methods: The in-vitro dissolution profile was obtained using 900 ml of phosphate buffer pH 6.8 with 1.0% SLS at 37 °C ± 0.5 °C as dissolution medium and USP II (paddle) at 75 rpm. The average % in-vitro drug release was above 80% within 45 minutes for the above drug combination. The drug release profile was evaluated by RP-HPLC method. Chromatographic separation was done on Hypersil-BDS C-18 (12.5cm x 4.6mm x 5μm) column using gradient program with initial mobile phase ratio of 55:45 (v/v) mixture of ammonium acetate buffer (pH 5.0) and acetonitrile at a flow rate of 1.0 ml/min with detection wavelength 260 nm. Results: The method was validated with respect to specificity, linearity, precision, accuracy, and robustness. The method was found to be linear in the range of 7.0-21.0 μg/ml for CHLR (R 2 = 0.9982), 22.5-67.5 μg/ml for OLM (R 2 = 0.9999) and 5.5 -16.5 μg/ml for CIL (R 2 = 0.9995) respectively. The % recovery data were found between 98.3 % to 104.1%. The % RSD for method and intermediate precision of method did not exceed more than 2%. Conclusion: The proposed in-vitro method can be applied successfully for routine quality control analysis to check the quality of above drug combination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Current pharmaceutical analysis - 18(2022), 6, Seite 13 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shah, Pranavkumar [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (13 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011170565 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011170565 | ||
| 003 | DE-627 | ||
| 005 | 20231128145746.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011170565 | ||
| 035 | |a (KFL)prod_DARH_.FBAF07977BEB3FE5C2E490E7E704BC4EF255E004 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Shah, Pranavkumar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a RP-HPLC In-Vitro Dissolution Method Development and Validation for Determination of Olmesartan Medoxomil, Chlorthalidone and Cilnidipine Drug Combinations |c Pranavkumar Shah, Bhavin Dhaduk |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (13 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective: A simple, sensitive, and accurate in-vitro dissolution method has been developed for Olmesartan Medoxomil (OLM), Chlorthalidone (CHLR) & Cilnidipine (CIL) drug combination according to USP dissolution testing methodologies with different discriminating mediums and validated as per ICH guidelines. Methods: The in-vitro dissolution profile was obtained using 900 ml of phosphate buffer pH 6.8 with 1.0% SLS at 37 °C ± 0.5 °C as dissolution medium and USP II (paddle) at 75 rpm. The average % in-vitro drug release was above 80% within 45 minutes for the above drug combination. The drug release profile was evaluated by RP-HPLC method. Chromatographic separation was done on Hypersil-BDS C-18 (12.5cm x 4.6mm x 5μm) column using gradient program with initial mobile phase ratio of 55:45 (v/v) mixture of ammonium acetate buffer (pH 5.0) and acetonitrile at a flow rate of 1.0 ml/min with detection wavelength 260 nm. Results: The method was validated with respect to specificity, linearity, precision, accuracy, and robustness. The method was found to be linear in the range of 7.0-21.0 μg/ml for CHLR (R 2 = 0.9982), 22.5-67.5 μg/ml for OLM (R 2 = 0.9999) and 5.5 -16.5 μg/ml for CIL (R 2 = 0.9995) respectively. The % recovery data were found between 98.3 % to 104.1%. The % RSD for method and intermediate precision of method did not exceed more than 2%. Conclusion: The proposed in-vitro method can be applied successfully for routine quality control analysis to check the quality of above drug combination | ||
| 700 | 1 | |a Dhaduk, Bhavin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical analysis |d Sharjah, U.A.E. : Bentham Science Publ., 2005 |g 18(2022), 6, Seite 13 |h Online-Ressource |w (DE-627)KFL000006440 |w (DE-600)2216923-4 |w (DE-576)306832917 |x 1875-676X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:6 |g pages:13 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1573-4129&volume=18&issue=6&spage=629 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 6 |h 13 | ||